Observed RSV-associated Cases in the First Week After Clesrovimab Immunization in the Phase 2b/3 CLEVER trial and Pharmacodynamic Modeling Suggest an Early Onset of Protection (ID 760)

Andrea Guerra, MD1; Xiaowei Zang, PhD1 ; Ying Zhang, PhD1; Radha A. Railkar, PhD1; and Anushua Sinha, MD, MPH1. Presented on behalf of the authors by Nidhi Seegobin, PhD2.

MSD (UK)

This abstract was previously presented at the British Society for Antimicrobial Chemotherapy (BSAC) Spring Conference 2026, 14-15 May 2026 in London,UK and at the RSVVW Conference; February 17-20, 2026; Rome, Italy.

Funding: This work was funded by Merck & Co., Inc., Rahway, NJ, USA.

Conflicts of interest: Andrea Guerra, Xiaowei Zang, Ying Zhang, Radha A. Railkar and Anushua Sinha are employees of Merck & Co., Inc. (USA).
Nidhi Seegobin is an employee of MSD (UK) Ltd.